All In Biotech

Drug Trial Radar · NCT07220902

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure: A Randomized Controlled Trial "LEVMag Trial"

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,240

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Dec 31, 2033

Study completion Jul 2034

Sponsor

Lead sponsor
Nebraska Methodist Health SystemAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including: severe allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.

Conditions

  • Severe Preeclampsia
  • Eclampsia Preeclampsia

Interventions

  • LevetiracetamDrug

    1g oral loading dose followed by 300mg q 8 hours beginning 8 hours after loading dose.

  • magnesium sulfateDrug

    4gram bolus followed by 2g per hour continuous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eclamptic SeizureTime frame: From enrollment until then end of monitoring at 6 weeks postpartum.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Methodist Women's Hospital

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.